Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 615-618, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paroni, R.
Right arrow Articles by Colombo, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paroni, R.
Right arrow Articles by Colombo, R.
Related Collections
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1997;43:615-618.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction

Rita Paronia, Cinzia Arcelloni, Elena De Vecchi, Isabella Fermo, Davide Mauri and Renzo Colombo

Laboratory of Chromatography and Separative Techniques and 1 Department of Urology, I.R.C.C.S. H San Raffaele, via Olgettina 60, 20132 Milano, Italy.
a Address correspondence to this author at: Lab. HPLC, H San Raffaele, Via Olgettina 60, 20132 Milano, Italy. Fax +39 2 26432640.

The aim of this study was to set up a method for quantification of plasma mitomycin C (MMC) concentrations during intravesical chemotherapy delivered in the presence of local bladder hyperthermia (HT). In comparison with existing methods, this assay, characterized by relative simplicity and efficiency, resulted in the facilitation of performance with nondedicated instrumentation or nonspecialized staff. Purification from plasma matrix was carried out by solid-phase extraction under vacuum. The purified drug was then collected directly into the vials of the HPLC autosampler. Chromatographic analysis was performed on a reversed-phase C18 column with water:acetonitrile (85:15 by vol) as the mobile phase and the UV detector set at 365 nm. The use of porfiromycin as internal standard provided a method with good within-day precision (CV 6.0% at 5 µg/L, n = 6), linearity (0.5–50 µg/L), and specificity. The lower limit of detection (<=0.5 µg/L) proved to be suitable for plasma pharmacokinetics monitoring in two tested patients treated with MMC+HT for superficial bladder cancer.


Key Words: indexing terms: plasma assay • bladder hyperthermia • intravesical chemotherapy • porfiromycin • pharmacokinetics






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.